版权说明 操作指南
首页 > 成果 > 详情

Effects of the lipoprotein lipase activator NO-1886 as a suppressor agent of atherosclerosis in aorta of mild diabetic rabbits

认领
导出
下载 Link by 万方学术期刊
反馈
分享
QQ微信 微博
成果类型:
期刊论文
作者:
Yin, WD*;Tsutsumi, K;Yuan, ZH;Yang, BT
通讯作者:
Yin, WD
作者机构:
[Yin, WD] Nanhua Univ, Coll Med, Inst Cardiovasc Res, Sch Med, Hengyang 421001, Hunan, Peoples R China.
Cent S Univ, Xiangya Med Coll, Dept Pathophysiol, Changsha, Hunan, Peoples R China.
Otsuka Pharmaceut Factory Inc, Res & Dev, Tokushima, Japan.
通讯机构:
[Yin, WD] N
Nanhua Univ, Coll Med, Inst Cardiovasc Res, Sch Med, Hengyang 421001, Hunan, Peoples R China.
语种:
英文
关键词:
[4-(4-Bromo-2-cyanophenylcarbamoyl)-benzyl]phosphonic acid diethyl ester;Atherosclerosis;CAS 133208-93-2;Diabetes mellitus;NO-1886, atherosclerosis suppression, plasma glucose levels;Rabbits
关键词(中文):
降血脂药;动脉硬化;苯甲酰胺类;糖尿病;实验性;脂蛋白脂酶;有机磷化合物
期刊:
ARZNEIMITTELFORSCHUNG-DRUG RESEARCH
ISSN:
0004-4172
年:
2002
卷:
52
期:
8
页码:
610-614
机构署名:
本校为第一且通讯机构
院系归属:
医学院
药学与生物科学学院
摘要:
The synthetic compound NO-1886 ([4-(4-bromo-2-cyano-phenylcarbamoyl)-benzyl]-phosphonic acid diethyl ester, CAS 133208-93-2) is a lipoprotein lipase activator which decreases plasma triglycerides and elevates high-density lipoprotein cholesterol (HDL-C) levels. However, the effects of NO-1886 on plasma glucose level and atherosclerosis in diabetes are not clear. The aim of this study was to ascertain whether the compound lowers plasma glucose and suppresses atherosclerosis in New Zealand White rabbits with high fat/high sucrose-induced mild diabetes. High fat/high sucrose feeding increased pla...

反馈

验证码:
看不清楚,换一个
确定
取消

成果认领

标题:
用户 作者 通讯作者
请选择
请选择
确定
取消

提示

该栏目需要登录且有访问权限才可以访问

如果您有访问权限,请直接 登录访问

如果您没有访问权限,请联系管理员申请开通

管理员联系邮箱:yun@hnwdkj.com